<DOC>
	<DOCNO>NCT00415324</DOCNO>
	<brief_summary>This trial study side effect best dose eribulin mesylate cisplatin treat patient advance solid tumors.Drugs use chemotherapy , eribulin mesylate cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>Eribulin Mesylate Cisplatin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Primary Objectives : I . To determine maximum tolerate dose E7389 cisplatin patient advance solid tumor . II . To determine safety toxicity regimen patient . III . To determine pharmacokinetics regimen patient . Outline : This multicenter , dose-escalation study . Patients receive eribulin mesylate IV 5 minute day 1 , 8 , 15 cisplatin IV 30-60 minute day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 8 week .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm malignant solid tumor Advanced disease , meet follow criterion : Metastatic unresectable disease standard curative palliative measure exist longer effective . No known active brain metastasis Life expectancy &gt; 3 month ECOG performance status 02 Bilirubin normal No uncontrolled intercurrent illness include , limited , follow : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness social situation would limit study compliance . Negative pregnancy test Fertile patient must use effective contraception Recovered prior therapy No prior chemotherapy within past 4 week ( 6 week nitrosoureas mitomycin C ) . No prior target therapy within past 4 week No prior immunotherapy within past 4 week No prior radiotherapy within past 4 week . No 2 prior chemotherapy regimen advance solid tumor . No concurrent investigational agent . Bisphosphonate therapy ( e.g. , pamidronate zolendronate ) consider investigational therapy . No concurrent antiretroviral therapy HIVpositive patient . No concurrent anticancer agent therapy . Tumor spread part body remove surgery . More 4 week since chemotherapy , biological therapy , radiation therapy . No two previous chemotherapy regimen advance solid tumor . WBC &gt; = 3,000/mm^3 Platelet count &gt; = 100,000/mm^3 Creatinine clearance &gt; = 60 mL/min Absolute neutrophil count &gt; = 1,500/mmÂ³ AST ALT = &lt; 2.5 time upper limit normal No prior cumulative cisplatin dose &gt; 300 mg/m^2 No preexisting neuropathy &lt; = grade 2 Not pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>